These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38127110)

  • 1. Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis.
    Aydin-Ghormoz EA; Perlmutter J; Koizumi N; Ortiz J; Faddoul G
    Clin Transplant; 2024 Jan; 38(1):e15225. PubMed ID: 38127110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
    Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
    Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.
    Leeaphorn N; Garg N; Khankin EV; Cardarelli F; Pavlakis M
    Transpl Int; 2018 Feb; 31(2):175-186. PubMed ID: 28926143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens.
    Aydin-Ghormoz E; Ortiz J; Koizumi N; Li MH; Faddoul G
    Pediatr Transplant; 2024 Jun; 28(4):e14783. PubMed ID: 38767019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.
    Von Visger JR; Gunay Y; Andreoni KA; Bhatt UY; Nori US; Pesavento TE; Elkhammas EA; Winters HA; Nadasdy T; Singh N
    Clin Transplant; 2014 Aug; 28(8):845-54. PubMed ID: 24869763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
    Sureshkumar KK; Hussain SM; Thai NL; Marcus RJ
    Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab Induction and Steroid Minimization in IgA Nephropathy: A Matched-Cohort Analysis.
    Becker K; Brooks J; Mitro G; Rees M; Ortiz J
    Exp Clin Transplant; 2020 Dec; 18(7):751-756. PubMed ID: 31875465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
    Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
    Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent IgA nephropathy after renal transplantation and steroid withdrawal.
    Di Vico MC; Messina M; Fop F; Barreca A; Segoloni GP; Biancone L
    Clin Transplant; 2018 Apr; 32(4):e13207. PubMed ID: 29345747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center long-term results of renal transplantation for IgA nephropathy.
    Bumgardner GL; Amend WC; Ascher NL; Vincenti FG
    Transplantation; 1998 Apr; 65(8):1053-60. PubMed ID: 9583865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of renal transplantation in patients with IgA nephropathy.
    Andresdottir MB; Hoitsma AJ; Assmann KJ; Wetzels JF
    Clin Nephrol; 2001 Oct; 56(4):279-88. PubMed ID: 11680657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy.
    Han SS; Huh W; Park SK; Ahn C; Han JS; Kim S; Kim YS
    Transpl Int; 2010 Feb; 23(2):169-75. PubMed ID: 19761553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
    Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
    Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of steroid maintenance on the outcomes in first-time deceased donor kidney transplant recipients: Analysis by induction type.
    Sureshkumar KK; Hussain SM; Thai NL; Ko TY; Nashar K; Marcus RJ
    World J Transplant; 2014 Sep; 4(3):188-95. PubMed ID: 25346892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation.
    Puliyanda DP; Pizzo H; Rodig N; Somers MJG
    Pediatr Transplant; 2020 May; 24(3):e13685. PubMed ID: 32112514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.